1. Mammalian target of rapamycin complex 1 is involved in differentiation of regenerating myofibers in vivo
- Author
-
Antonio Carlos Oliveira, Rui Curi, Anselmo Sigari Moriscot, Marcelo Saldanha Aoki, Jarlei Fiamoncini, Elen Haruka Miyabara, Rafael Herling Lambertucci, Igor L. Baptista, Meiricris T. Silva, Patricia Chakur Brum, Tania Cristina Pithon-Curi, Talita C. Conte, C. S. M. Serra, and Carlos Roberto Bueno
- Subjects
Soleus muscle ,medicine.medical_specialty ,Physiology ,Regeneration (biology) ,Skeletal muscle ,mTORC1 ,Biology ,Cellular and Molecular Neuroscience ,medicine.anatomical_structure ,Endocrinology ,Physiology (medical) ,Internal medicine ,Myosin ,medicine ,Myocyte ,Tetanic contraction ,Neurology (clinical) ,medicine.symptom ,Muscle contraction - Abstract
This work was undertaken to provide further insight into the role of mammalian target of rapamycin complex 1 (mTORC1) in skeletal muscle regeneration, focusing on myofiber size recovery. Rats were treated or not with rapamycin, an mTORC1 inhibitor. Soleus muscles were then subjected to cryolesion and analyzed 1, 10, and 21 days later. A decrease in soleus myofiber cross-section area on post-cryolesion days 10 and 21 was accentuated by rapamycin, which was also effective in reducing protein synthesis in these freeze-injured muscles. The incidence of proliferating satellite cells during regeneration was unaltered by rapamycin, although immunolabeling for neonatal myosin heavy chain (MHC) was weaker in cryolesion+rapamycin muscles than in cryolesion-only muscles. In addition, the decline in tetanic contraction of freeze-injured muscles was accentuated by rapamycin. This study indicates that mTORC1 plays a key role in the recovery of muscle mass and the differentiation of regenerating myofibers, independently of necrosis and satellite cell proliferation mechanisms.
- Published
- 2010